5 news items
Avenue Therapeutics to Host Virtual Key Opinion Leader (KOL) Event on April 4, 2024
ATXI
FBIO
25 Mar 24
capital expenditures to expand our research and development and manufacturing capabilities; expectations for generating revenue or becoming profitable
Avenue Therapeutics Reports Full Year 2023 Financial Results and Recent Corporate Highlights
ATXI
FBIO
18 Mar 24
: Research and development expenses for the full year 2023 were $6.1 million, compared to $2.7 million in 2022. Additionally, there was $4.2 million in expense
Avenue Therapeutics Receives Positive Listing Determination from Nasdaq
ATXI
FBIO
15 Mar 24
or in-license; our use of clinical research centers and other contractors; expectations for incurring capital expenditures to expand our research
Avenue Therapeutics to Present BAER-101 Preclinical Data at American Society for Experimental Neurotherapeutics (ASENT) 2024 Annual Meeting
ATXI
FBIO
11 Mar 24
research centers and other contractors; expectations for incurring capital expenditures to expand our research and development and manufacturing
Avenue Therapeutics Announces Publication in Drug Development Research Highlighting First-In-Class Preclinical Data of BAER-101 in a Translational Model of Absence Epilepsy
ATXI
FBIO
22 Feb 24
for incurring capital expenditures to expand our research and development and manufacturing capabilities; expectations for generating revenue or becoming
- Prev
- 1
- Next